Abstract
There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by 40% of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 835-842 |
| Number of pages | 8 |
| Journal | American Journal of Gastroenterology |
| Volume | 106 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2011 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
Cite this
Opioid-induced constipation : Challenges and therapeutic opportunities. / Camilleri, Michael.
In: American Journal of Gastroenterology, Vol. 106, No. 5, 05.2011, p. 835-842.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Opioid-induced constipation
T2 - Challenges and therapeutic opportunities
AU - Camilleri, Michael
PY - 2011/5
Y1 - 2011/5
N2 - There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by 40% of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC.
AB - There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by 40% of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC.
UR - http://www.scopus.com/inward/record.url?scp=79955578050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955578050&partnerID=8YFLogxK
U2 - 10.1038/ajg.2011.30
DO - 10.1038/ajg.2011.30
M3 - Article
VL - 106
SP - 835
EP - 842
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
SN - 0002-9270
IS - 5
ER -